ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 249

Where to Look for Uric Acid Crystals? Results from a Norwegian Ultrasound Study

Hilde B Hammer1, Lars Karoliussen2, Lene Terslev3, Espen A. Haavardsholm4, Tore K Kvien5 and Till Uhlig4, 1Rheumatology, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 4Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5On behalf of the NOR-DMARD registry, Oslo, Norway

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Crystal-induced arthritis, gout and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Imaging of Rheumatic Diseases Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Ultrasound (US) has received an increasing attention in detecting uric monosodium urate (MSU) deposits, and is included in the ACR/EULAR classification criteria for gout. The OMERACT US group has developed definitions for US elementary lesions in gout including double contour (DC) sign (deposits of crystals on the surface of cartilage), tophus (larger hypo-echoic aggregation of crystals, usually well delineated), aggregates (small hyper-echoic deposits) and erosions. MSU deposits may be found in many different regions in an individual with gout but with some predilection sites. The present objective was to asses by US the presence of MSU deposits in a high number of locations known to be involved, and to identify areas to include when screening for gout by US.

Methods:

This includes baseline data from a prospective observational study where patients with crystal-proven gout who presented after a recent gout flare were included (117 patients (mean (SD) 56.9 (14.1) years old, 8.5 (7.3) years disease duration, 93.2% men), all with insufficiently treated serum uric acid level (>360 μmol/L/>6 mg/dl). We performed a systematic extensive assessment with US (GE E9 machine, grey scale 15MHz) to detect MSU deposits, using the OMERACT definitions for DC, tophi and aggregates. The following locations were assessed bilaterally; radiocarpal joint, MCP 2, insertion of triceps and quadriceps, the patellar tendon (divided into proximal and distal), cartilage of distal femur (maximal flexed knee) and the talar cartilage of the tibiotalar joint, the MTP 1 joint as well as the Achilles tendon. Sum of sites with deposits was calculated and correlations were performed by use of Spearman, and frequencies of deposits were calculated as percentages at each site.

Results:

The mean (SD) serum uric acid level was 488 (88) μmol/L. There was no significant correlation between number of sites with deposits and uric acid level (r=0.11), but with disease duration (r=0.25, p=0.007). The table shows that DC was primarily found in MTP1, followed by talar and femoral cartilage. Tophi and aggregates were primarily found in MTP1, followed by distal patellar and triceps tendons. There were no major differences between right and left side. In 21 patients (17.9%) DC was seen on femoral or talar cartilage, but not in the MTP1 joints.

Conclusion:

There is limited knowledge on the primary locations of MSU deposits, and the present study suggests US examinations of MTP1, distal patellar and triceps tendons as well as talar and femoral cartilage to be the most important sites to explore for presence of MSU deposits in patients examined for possible gout.

Double contour

Tophus

Aggregates

Right

Left

Right

Left

Right

Left

Wrist

1.7

0

7.7

9.5

7.7

8.6

MCP 2

0

0

3.5

1.8

2.6

1.7

Distal femur cartilage

15.3

16.1

NA

NA

NA

NA

Talar cartilage

18.8

19.7

NA

NA

NA

NA

MTP 1

36.2

32.5

44.0

45.7

46.5

53.0

Triceps

NA

NA

18.0

14.5

29.1

30.8

Quadriceps

NA

NA

6.0

11.9

10.3

19.7

Proximal patellar tendon

NA

NA

4.3

7.7

10.4

12.0

Distal patellar tendon

NA

NA

22.4

17.1

42.2

39.3

Achilles

NA

NA

8.7

8.7

11.3

6.1


Disclosure: H. B. Hammer, AbbVie Norway, 2,Abbvie, 8,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 8,Roche Pharmaceuticals, 8; L. Karoliussen, None; L. Terslev, None; E. A. Haavardsholm, None; T. K. Kvien, AbbVie, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,UCB, 2,BMS, 2,MSD, 2,AbbVie, 5,Pfizer Inc, 5,BMS, 8,MSD, 8,Roche Pharmaceuticals, 8,UCB, 8,AbbVie, 8; T. Uhlig, None.

To cite this abstract in AMA style:

Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T. Where to Look for Uric Acid Crystals? Results from a Norwegian Ultrasound Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/where-to-look-for-uric-acid-crystals-results-from-a-norwegian-ultrasound-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/where-to-look-for-uric-acid-crystals-results-from-a-norwegian-ultrasound-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology